Bristol-Myers Squibb Shares Rise 1.35% as 0.47 Billion Volume Ranks 222nd Amid MYK-224 Trial Termination and Opdivo Pipeline Gains

On August 12, 2025, Bristol-Myers Squibb (BMY) rose 1.35% with a trading volume of $0.47 billion, ranking 222nd in daily trading activity. The stock’s performance followed the termination of its Phase 2a clinical trial for MYK-224, a candidate for obstructive hypertrophic cardiomyopathy. The study, which began in January 2023, was halted without further details disclosed, raising questions about the drug’s development timeline and potential market impact. Analysts noted the termination could delay therapeutic alternatives for a niche patient population, though the company remains focused on its broader pipeline advancements.

Recent developments highlighted BMY’s ongoing efforts to strengthen its oncology portfolio. Positive outcomes from a Phase 3 trial of Opdivo in non-small cell lung cancer underscored the drug’s potential in expanding indications, bolstering investor confidence. Meanwhile, institutional ownership remains robust at 76.41%, reflecting sustained institutional trust. Short interest decreased by 2.71% in the prior month, signaling improving sentiment amid mixed analyst ratings, which remain split between hold and buy recommendations.

A strategy of holding the top 500 volume-driven stocks for one day yielded $2,300 in profit from 2022 to the present, though it faced a maximum drawdown of -15.7% in early 2023. This underscores the inherent volatility of volume-based trading, even as BMY’s diversified pipeline and dividend sustainability—supported by a projected 40.72% payout ratio next year—position it for long-term resilience.